News
Sanofi tightens grip on RSV, paying $1.15B upfront for Vicebio and boosting its pipeline beyond mRNA
Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing preclin | Sanofi has struck a deal to buy Vicebio ...
(Reuters) -French pharmaceuticals company Sanofi said on Tuesday it would acquire British private biotechnology firm Vicebio ...
The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV ...
Dealbreaker on MSN5d
Sanofi Extends Respiratory Vaccines Reach With $1.15B Acquisition of Clinical-Stage VicebioThe deal complements an existing partnership with Novavax that encompasses R&D of combination vaccines for Covid-19 and flu.
PARIS] Sanofi agreed to buy UK biotech Vicebio for as much as US$1.6 billion, gaining experimental vaccines and a technology ...
Sanofi has moved to bolster its vaccines business by reaching a deal to buy London, UK-based biotech Vicebio, which was ...
Sanofi SA (NASDAQ:SNY) on Tuesday agreed to acquire Vicebio Ltd, a privately held biotechnology company headquartered in ...
Paris: Sanofi has announced it has entered into an agreement to acquire Vicebio Ltd, a privately held biotechnology company ...
News-Medical.Net on MSN3d
New model predicts mRNA protein production, accelerating drug and vaccine discoveryA new artificial intelligence model can improve the process of drug and vaccine discovery by predicting how efficiently ...
Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline Paris, July 22, 2025. Sanofi today announces it has entered into an agreement to acquire Vicebio Ltd (“Vicebio”), a privately held ...
French pharma giant Sanofi announced on Tuesday that it is to purchase London-based respiratory virus vaccine developer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback